“We’re not trying to win on the latest craze here,” Song said. “We’re looking for long-term investors who have an interest in technology and innovation and see the recent bear market in biotech as an opportunity to allocate capital here and own quality companies over the next 5-10 years given really favorable starting valuations.” 

First « 1 2 » Next